orenitram earn freedom gener
announc settlement actavi orenitram patent litig
term agreement grant actavi licens
manufactur commerci gener orenitram begin june
possibl earlier certain circumst settlement
agreement permit actavi manufactur gener version
product previous model entri orenitram
news moder posit chang
long-term thesi orenitram face competit pressur jnj uptravi
gener view prefer oral prostacyclin agent pah
given titrat toler issu associ orenitram longer term
see potenti competit arna ralinepag start
demonstr promis profil studi
rais stake orenitram freedom-ev updat model
reflect orenitram gener competit start ad
tp base expect scenario freedom-ev outlin
initi see potenti upsid though believ
probabl success slightli
stat-signific clinic meaning impact tyvaso
 base case
valuat reiter under-perform rate increas tp
valuat base blend dcf project risk
thesi includ failure/delay gener competitor limit adopt
gener overwhelmingli posit outcom freedom-ev trial
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
unit therapeut corpor biotechnolog compani
focus develop commerci product
treatment chronic life-threaten condit
price feb rate under-perform target price analyst martin auster
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
cash-flow financ activ
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
posit clinic meaning freedom-ev remosynch
remunity/remopro success captur new
freedom-ev failur remosynch captur iv new
start remunity/remopro failur
 close
compani mention price
